• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients.

作者信息

Frerichs Kristine A, Bosman Patricia W C, van Velzen Jeroen F, Fraaij Pieter L A, Koopmans Marion P G, Rimmelzwaan Guus F, Nijhof Inger S, Bloem Andries C, Mutis Tuna, Zweegman Sonja, van de Donk Niels W C J

机构信息

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam.

University Medical Center, Laboratory of Translational Immunology, Utrecht.

出版信息

Haematologica. 2020 Jun;105(6):e302-e306. doi: 10.3324/haematol.2019.231860. Epub 2019 Sep 26.

DOI:10.3324/haematol.2019.231860
PMID:31558675
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7271608/
Abstract
摘要

相似文献

1
Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients.达雷妥尤单抗对接受过广泛预处理的多发性骨髓瘤患者正常浆细胞、多克隆免疫球蛋白水平及疫苗接种反应的影响。
Haematologica. 2020 Jun;105(6):e302-e306. doi: 10.3324/haematol.2019.231860. Epub 2019 Sep 26.
2
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.监测接受达雷妥尤单抗治疗的多发性骨髓瘤患者：揭示单克隆抗体干扰。
Clin Chem Lab Med. 2016 Jun 1;54(6):1095-104. doi: 10.1515/cclm-2015-1031.
3
Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.达雷妥尤单抗和卡非佐米对新诊断的间变性多发性骨髓瘤疗效不佳。
J Clin Exp Hematop. 2020;60(1):17-20. doi: 10.3960/jslrt.19031.
4
Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.CD38 复合物的晶体结构，其中 daratumumab 是一种治疗多发性骨髓瘤的首创抗 CD38 抗体药物。
Biochem Biophys Res Commun. 2021 Jan 15;536:26-31. doi: 10.1016/j.bbrc.2020.12.048. Epub 2020 Dec 22.
5
VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months.VS38 鉴定出在达雷妥尤单抗治疗后 CD38 弱表达的骨髓瘤细胞和浆细胞，这会干扰 CD38 检测达 4 至 6 个月。
Am J Clin Pathol. 2020 Jan 2;153(2):221-228. doi: 10.1093/ajcp/aqz153.
6
Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.接受抗CD38单克隆抗体达雷妥尤单抗治疗多发性骨髓瘤患者的输血前免疫血液学检测的注意事项
Intern Med J. 2018 Feb;48(2):210-220. doi: 10.1111/imj.13707.
7
Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).达雷妥尤单抗会干扰多发性骨髓瘤患者的血清免疫固定电泳监测，使用达雷妥尤单抗免疫固定电泳反射检测（DIRA）可消除这种干扰。
Clin Chem Lab Med. 2016 Jun 1;54(6):1105-9. doi: 10.1515/cclm-2015-0888.
8
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.EMA 对达雷妥尤单抗治疗多发性骨髓瘤成人患者的评估。
Oncologist. 2018 May;23(5):594-602. doi: 10.1634/theoncologist.2017-0328. Epub 2018 Jan 25.
9
[Daratumumab for multiple myeloma].达雷妥尤单抗用于治疗多发性骨髓瘤
Bull Cancer. 2018 Nov;105(11):985-991. doi: 10.1016/j.bulcan.2018.09.003. Epub 2018 Oct 24.
10
Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by -Expanded Autologous NK Cells.达雷妥尤单抗治疗多发性骨髓瘤导致 NK 细胞亲缘性杀伤被扩增的自体 NK 细胞所克服。
Clin Cancer Res. 2018 Aug 15;24(16):4006-4017. doi: 10.1158/1078-0432.CCR-17-3117. Epub 2018 Apr 17.

引用本文的文献

1
Updated Review for Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection.无HIV感染的免疫抑制女性宫颈癌筛查指南的更新综述
J Low Genit Tract Dis. 2025 Apr 1;29(2):168-179. doi: 10.1097/LGT.0000000000000866. Epub 2025 Jan 13.
2
Supportive care in myeloma-when treating the clone alone is not enough.骨髓瘤的支持性护理——当仅治疗克隆细胞不足够时。
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):569-581. doi: 10.1182/hematology.2024000579.
3
Open-Label Phase 1/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation.基于达雷妥尤单抗的肾移植前脱敏开放标签1/2期研究
Kidney Int Rep. 2024 Aug 26;9(11):3250-3264. doi: 10.1016/j.ekir.2024.08.020. eCollection 2024 Nov.
4
Immunoglobulin Replacement Therapy: Insights into Multiple Myeloma Management.免疫球蛋白替代疗法：对多发性骨髓瘤管理的见解
Cancers (Basel). 2024 Sep 18;16(18):3190. doi: 10.3390/cancers16183190.
5
COVID-19 vaccine updates for people under different conditions.不同人群的 COVID-19 疫苗更新信息。
Sci China Life Sci. 2024 Nov;67(11):2323-2343. doi: 10.1007/s11427-024-2643-1. Epub 2024 Jul 29.
6
Respiratory syncytial virus and other vaccine-preventable infections in multiple myeloma. A population-based study on 8,672 myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry.呼吸道合胞病毒及其他可通过疫苗预防的感染在多发性骨髓瘤中的情况。一项基于人群的研究，研究对象为2008年至2021年期间从瑞典骨髓瘤登记处确诊的8672例骨髓瘤患者。
Haematologica. 2025 Jan 1;110(1):179-182. doi: 10.3324/haematol.2024.285161.
7
Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma.抗 CD38 与检查点抑制剂治疗 NK/T 细胞淋巴瘤的不良反应。
Front Immunol. 2024 Apr 12;15:1346178. doi: 10.3389/fimmu.2024.1346178. eCollection 2024.
8
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab.对接受达雷妥尤单抗治疗的结外自然杀伤/T 细胞淋巴瘤患者进行免疫分析。
Ann Hematol. 2024 Jun;103(6):1989-2001. doi: 10.1007/s00277-023-05603-w. Epub 2024 Jan 18.
9
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.特卡昔单抗可损害经大量预处理的骨髓瘤患者的体液免疫：免疫球蛋白补充的重要性。
Blood Adv. 2024 Jan 9;8(1):194-206. doi: 10.1182/bloodadvances.2023011658.
10
COVID-19 vaccine immune response in patients with plasma cell dyscrasia: a systematic review.浆细胞发育异常患者的COVID-19疫苗免疫反应：一项系统综述
Ther Adv Vaccines Immunother. 2023 Aug 27;11:25151355231190497. doi: 10.1177/25151355231190497. eCollection 2023.

本文引用的文献

1
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于新诊断多发性骨髓瘤患者自体造血干细胞移植前后（CASSIOPEIA）：一项随机、开放标签、3 期研究。
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
2
Daratumumab plus lenalidomide and dexamethasone lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.达雷妥尤单抗联合来那度胺和地塞米松 vs. 来那度胺和地塞米松治疗复发或难治性多发性骨髓瘤：POLLUX 更新分析。
Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.
3
The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis.免疫抑制剂对肺炎球菌疫苗免疫原性的影响：系统评价和荟萃分析。
Vaccine. 2018 Sep 18;36(39):5832-5845. doi: 10.1016/j.vaccine.2018.07.039. Epub 2018 Aug 16.
4
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.自体造血干细胞移植后接受来那度胺维持治疗的多发性骨髓瘤患者进行再接种是安全有效的。
Biol Blood Marrow Transplant. 2018 Apr;24(4):871-876. doi: 10.1016/j.bbmt.2017.12.795. Epub 2017 Dec 27.
5
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.在接受达雷妥尤单抗治疗的患者中，单核细胞和粒细胞降低骨髓瘤细胞上 CD38 的表达水平。
Clin Cancer Res. 2017 Dec 15;23(24):7498-7511. doi: 10.1158/1078-0432.CCR-17-2027. Epub 2017 Oct 12.
6
Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial.浆细胞疾病患者接种两剂高剂量流感疫苗后的临床和血清学反应：一项前瞻性单臂试验
Clin Lymphoma Myeloma Leuk. 2017 May;17(5):296-304.e2. doi: 10.1016/j.clml.2017.02.025. Epub 2017 Mar 7.
7
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.在先前接受蛋白酶体抑制剂和免疫调节药物治疗的复发或难治性多发性骨髓瘤患者中，达雷妥尤单抗静脉输注后的药代动力学。
Clin Pharmacokinet. 2017 Aug;56(8):915-924. doi: 10.1007/s40262-016-0477-1.
8
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.Daratumumab 单药治疗多发性骨髓瘤中针对 CD38。
N Engl J Med. 2015 Sep 24;373(13):1207-19. doi: 10.1056/NEJMoa1506348. Epub 2015 Aug 26.
9
Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma.多发性骨髓瘤患者中流感病毒单剂量疫苗与加强疫苗接种的效果比较
Haematologica. 2015 Jul;100(7):e285-8. doi: 10.3324/haematol.2014.116772. Epub 2015 Mar 27.
10
Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours.成人实体瘤患者化疗期间接种流感病毒疫苗的血清抗体反应。
Vaccine. 2013 Dec 16;31(52):6177-84. doi: 10.1016/j.vaccine.2013.10.053. Epub 2013 Oct 29.